Ultragenyx Pharma (RARE) Misses Q1 EPS by 6c

Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.35), $0.06 worse than the analyst estimate of ($1.29).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Solstice acquiring Element Solutions in $14.5B cash and stock deal
• Lynx Equity on Lam Research (LRCX): 'Closing in on full valuation'
• Proto Labs (PRLB) PT Raised to $91 at Benchmark on Meeting and Exceeding Previous Target